Featured Insights
-
Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ
1/6/2025
The FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including the importance of early engagement with the FDA, CMC considerations, and more.
-
Partnering With Health Systems: Essential Tips For CGT Commercialization
12/5/2025
Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
-
Addressing A Critical Drug Shortage
4/20/2026
A critical drug shortage demanded regulatory action, importation support, and patient program readiness. See how integrated QA, 3PL, and PSP capabilities delivered operational readiness in three months.
-
Streamlining European Expansion With Integrated PV, Regulatory, And Commercial Expertise
4/17/2026
See how a single-provider model integrated pharmacovigilance with regulatory and commercialization support to support a scalable, audit-ready system that strengthened compliance and freed internal resources for growth.
-
5 Operational Gaps To Avoid CGT Patient Risks
5/27/2026
Examine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies.
-
Cell And Gene Therapy Commercialization Handbook
11/24/2025
Bringing advanced therapeutics to market requires overcoming hurdles in regulation, logistics, and reimbursement. Learn how to coordinate supply chains and implement adaptive strategies for long-term commercial success.
-
Inside The Payer Perspective On Cell And Gene Therapy Coverage
3/2/2026
Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
-
A Thoughtful Copay Program Design That Increased Patient Engagement
11/26/2024
Learn how a partnership with a pharmaceutical company to redesign patient support materials resulted in increased patient engagement and copay program utilization.
-
Navigating The Cell And Gene Regulatory Landscape
10/3/2024
Navigating the complex regulatory landscape is essential for cell and gene therapy success. Explore key considerations, challenges, and best practices for companies operating in this space.
-
Understanding The EU Regulatory Landscape For Cell And Gene Therapies
4/9/2026
EU approval for cell and gene therapies isn't just a different process, it's a different playbook. Here's what US manufacturers need to know before they engage.